Morpeth facility marks two decades with new tablet press acquisition

  • Piramal Pharma Solutions celebrates two decades at its Morpeth facility.
  • The company has acquired a Korsch X3 tablet press to enhance production.
  • The investment reflects the company's commitment to pharmaceutical advancements.

Piramal Pharma Solutions is marking the 20th anniversary of its Morpeth facility, a key site in its pharmaceutical manufacturing operations. To celebrate this milestone, the company has invested in a new Korsch X3 tablet press, which is expected to optimize tablet production capabilities. This acquisition highlights the firm's ongoing commitment to excellence and growth in the pharmaceutical sector.

The Korsch X3 tablet press will enable increased efficiency and output in the tablet manufacturing process at the Morpeth site. This addition aligns with Piramal Pharma Solutions' strategy to enhance its production and meet rising market demands. The facility has been integral in providing high-quality pharmaceutical products and services for clients globally.

Since its establishment, the Morpeth facility has played a significant role in the growth of Piramal Pharma Solutions. The procurement of the Korsch X3 tablet press is part of continuous investments aimed at advancing manufacturing technologies and improving service offerings in the industry. This anniversary is not just a celebration but also a reaffirmation of the company's dedication to innovation in pharmaceutical manufacturing.

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

BD Helps Scientists Advance Immunology and Cancer Research with AI-Powered Insights and Automation

Innovative automation enhances cancer research and immunological studies. AI-powered tools improve research…

Services PMI at 53.8 in January 2026, According to ISM Report

January sees strong growth in services sector as PMI remains robust. Services…

Pharmacelera Raises $6M to Expand in US and Enhance Drug Discovery Platform

Funding will support growth and technological advancements in drug discovery. Pharmacelera has…

WuXi Biologics and Vertex Enter Research Agreement for T-Cell Engager

Collaboration focuses on advancing T-cell engager therapies for cancer treatment WuXi Biologics…